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Therapy for Tuberculous Meningitis
To the Editor: Heemskerk et al. (Jan. 14 issue)1 
report no survival benefit for intensified antitu-
berculosis treatment for patients with tubercu-
lous meningitis in Vietnam, a finding that was 
contrary to the results of our study in Indonesia.2 
Our unblinded study was smaller and had a high-
er proportion of patients with advanced tuber-
culous meningitis. However, we think that the 
contrasting results are explained by the dose of 
rifampin that was administered. The Vietnam 
study compared 10 mg of rifampin per kilogram 
of body weight per day with an increased dose of 
15 mg of rifampin per kilogram, whereas we 
evaluated 13 mg of rifampin per kilogram ad-
ministered intravenously. The high dose used in 
our study resulted in an increase in rifampin ex-
posure in blood and cerebrospinal fluid by a fac-
tor of 3, with a relationship between the drug 
level and the therapeutic response.3 In our study, 
38% of patients who were receiving 13 mg of rif-
ampin per kilogram had drug exposure that was 
lower than the target exposure, which suggests 
that the dose was not high enough.
Recent trial data for pulmonary tuberculosis 
also support higher doses of rifampin than that 
used in the Vietnam study. Regimens consisting 
of doses of less than 35 mg of rifampin per kilo-
gram did not reduce the time to culture conver-
sion.4 We are currently evaluating similarly in-
creased rifampin doses for the treatment of 
tuberculous meningitis to prepare for a phase 3 
trial. Pharmacokinetic and pharmacodynamic 
analyses may show how many patients in the 
Vietnam trial with its modest dose increase 
reached target exposures of rifampin.3
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To the Editor: Heemskerk et al. investigated 
an “intensified” treatment for tuberculous men-
ingitis and did not find a higher survival rate 
than that with standard treatment. We think 
that the dose of rifampin was too low. We have 
shown that doses up to 35 mg per kilogram are 
tolerated.1,2 The authors suggest that the bene-
fits of rifampin may be modest. Our data show 
that higher doses of rifampin were associated 
with a faster decline in the bacterial load, which 
suggests that enhanced efficacy can occur with 
higher doses. Thus, it is difficult to draw con-
clusions about the failure of the experimental 
regimen when the trial regimen was possibly sub-
optimal.
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To the Editor: The study by Heemskerk et al. 
raises important questions about the approach to 
the treatment of tuberculous meningitis. The 
Kaplan–Meier curve for mortality in the sub-
group with grade 3 disease according to British 
Medical Research Council criteria appeared to 
favor the intensified-treatment regimen until it 
began to converge with that of the standard-
treatment regimen around day 150. A brief, but 
less substantial, divergence of the curves was 
seen early on in other subgroups as well. This 
raises the question as to whether a more pro-
longed intensive-treatment strategy might be 
beneficial. This approach is not without prece-
dent, as described by Donald et al. in the edito-
rial accompanying the article1 and in a study of 
intensive therapy.2 Although most new regimens 
that are evaluated have focused on reducing the 
duration of treatment or modifying the intensive 
phase in patients with pulmonary tuberculosis,3 
perhaps the use of multiple drugs for longer pe-
riods may have an effect on mortality in patients 
with tuberculous meningitis.
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The authors reply: We agree with all three 
groups of correspondents that higher doses of 
rifampin, perhaps given throughout treatment 
after initial intravenous administration, may yet 
improve outcomes for patients with tuberculous 
meningitis. This effect, however, is predicated on 
the hypothesis that enhanced intracerebral kill-
ing of Mycobacterium tuberculosis by “intensified” 
antituberculosis treatment will increase survival 
from tuberculous meningitis.
There are good reasons to question this hy-
pothesis. First, our trial tested the addition of 
higher-dose rifampin and levofloxacin to standard 
four-drug treatment for the first 2 months of 
therapy. Leaving aside the chosen rifampin dose, 
levofloxacin is highly active against M. tuberculo-
sis, and oral administration of the dose used in 
the trial achieves high concentrations in the cere-
brospinal fluid.1 Yet the addition of levofloxacin 
to treatment had no discernible effect on sur-
vival from tuberculous meningitis.
Unlike pulmonary tuberculosis, tuberculous 
meningitis is caused by a small number of bac-
teria. This fact hampers both the microbiologic 
diagnosis and investigations linking drug expo-
sures with destruction of bacteria and clinical 
outcomes, but neither the bacterial load in cere-
brospinal fluid nor the time to its sterility has 
ever been clearly linked with survival among 
patients with tuberculous meningitis.2 Instead, 
the clinical outcome has been much more close-
ly associated with the intracerebral inflamma-
tory response, which may explain why the use of 
adjunctive glucocorticoids improves survival3 and 
why intensifying antituberculosis treatment has 
so far met with limited success.
In addition, increased doses of antituberculo-
sis drugs increase the risk of drug-induced hepatic 
toxicity. In patients with pulmonary tuberculosis, 
this complication can usually be managed safely 
by stopping the drugs and reintroducing them 
slowly. But in patients with tuberculous menin-
gitis, any interruption in treatment with antitu-
berculosis drugs is an independent risk factor 
for death.3 This suggests that any potential sur-
vival benefit of intensified regimens may be offset 
by even moderately increased toxicity and conse-
quent reductions in dose or withdrawal of drugs.
In patients with tuberculous meningitis, sur-
vival depends on controlling inflammation and 
killing bacteria before the development of com-
plications of advanced disease: hydrocephalus, 
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infarction, tuberculomas, and coma. Diagnos-
tic delay and the failure to start antituberculosis 
drugs before the onset of coma is the strongest 
predictor of death from tuberculous meningitis.4 
The extent to which enhanced killing of bacteria 
through intensified antituberculosis regimens 
might improve outcomes remains a question 
worth asking, but it should not detract from the 
need to find better diagnostic tests and to better 
understand and control the immunopathology 
of the disease.
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Planned Out-of-Hospital Birth and Birth Outcomes
To the Editor: Snowden et al. (Dec. 31 issue)1 
report increased mortality among neonates in 
Oregon whose mothers had planned out-of-hos-
pital births and therefore corroborate our previ-
ous findings of significantly increased risks of 
perinatal deaths and neonatal seizures among 
neonates whose mothers had out-of-hospital 
births in the United States.2-4 Snowden et al. un-
deniably underestimate the absolute and relative 
neonatal risks associated with out-of-hospital 
births, specifically with home births. First, they 
lump together the outcomes for infants born in 
birthing centers (which are associated with better 
outcomes and have a better selection of patients) 
with the outcomes for those whose mothers had 
planned home births.2 Second, they excluded de-
liveries associated with higher risk (twins, breech 
births, and anomalous births).1 Both the absolute 
risk and the relative risk of death for infants 
whose mothers have home births are therefore 
likely to be even greater than the authors report. 
Reducing the risks of childbirth is an ethical im-
perative for professionals in perinatal care who 
are committed to increasing the safety and im-
proving the quality of childbirth.5 Women plan-
ning an out-of-hospital birth should be informed 
of the modern perinatal interventions available 
in the hospital that are often lifesaving and can 
prevent the increased neonatal risks associated 
with planned out-of-hospital births.
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To the Editor: Snowden et al. report higher 
rates of perinatal death, depressed 5-minute 
Apgar scores, neonatal seizures, and maternal 
blood transfusions among births that occur out 
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